By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS








Company News
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015 8:31:26 AM
Pharmacyclics (PCYC) Release: New ibrutinib (IMBRUVICA) Data To Be Presented At American Association for Cancer Research Meeting 3/19/2015 10:17:29 AM
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015 5:57:01 AM
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/17/2015 5:56:00 AM
Inside The $21 Billion Bidding War For Pharmacyclics (PCYC) 3/6/2015 6:52:51 AM
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/5/2015 12:45:43 PM
AbbVie (ABBV) Outbids Johnson & Johnson (JNJ) and Lands Pharmacyclics (PCYC) for $21 Billion 3/5/2015 5:58:43 AM
Pharmacyclics (PCYC) Release: In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3/2/2015 6:51:04 AM
Market Analysis: Pharmacyclics (PCYC) Sale Good Idea if Buyer Understands Imbruvica Potential, Says Analyst 2/26/2015 3:14:26 PM
Bay Area's Pharmacyclics (PCYC) Mulls Possible $18 Billion Sale; Johnson & Johnson (JNJ),Novartis AG (NVS) Interested 2/26/2015 5:53:26 AM
12345678910...
//-->